These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8613969)

  • 1. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
    Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators.
    Bounameaux H; Ehringer H; Gast A; Hulting J; Rasche H; Rapold HJ; Reber G; Tschopp TB
    Thromb Haemost; 1999 Apr; 81(4):498-501. PubMed ID: 10235427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
    Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
    Jackson CV; Bailey BD; Shetler TJ
    J Pharmacol Exp Ther; 2000 Dec; 295(3):967-71. PubMed ID: 11082430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ; Sitko GR; Lehman ED; Vlasuk GP
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
    Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR
    J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK; Elokdah H; Leal M; Ji A; Friedrichs GS; Morgan GA; Swillo RE; Antrilli TM; Hreha A; Crandall DL
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis.
    Leadley RJ; Humphrey WR; Erickson LA; Shebuski RJ
    Thromb Haemost; 1995 Dec; 74(6):1583-90. PubMed ID: 8772241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
    Cadroy Y; Caranobe C; Bernat A; Maffrand JP; Sié P; Boneu B
    Thromb Haemost; 1987 Aug; 58(2):764-7. PubMed ID: 3672429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
    Carteaux JP; Gast A; Tschopp TB; Roux S
    Circulation; 1995 Mar; 91(5):1568-74. PubMed ID: 7867200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.